B
Bangkok Lab and Cosmetic PCL
SET:BLC
Bangkok Lab and Cosmetic PCL
SET:BLC
Price:
4.06
THB
1%
Market Closed
Market Cap:
฿2.4B
Balance Sheet
Balance Sheet Decomposition
Bangkok Lab and Cosmetic PCL
Bangkok Lab and Cosmetic PCL
Balance Sheet Decomposition is not available for
Bangkok Lab and Cosmetic PCL
Bangkok Lab and Cosmetic PCL
Balance Sheet
Bangkok Lab and Cosmetic PCL
Bangkok Lab and Cosmetic PCL
Currency: THB
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
2
|
10
|
8
|
22
|
38
|
90
|
180
|
|
| Cash Equivalents |
2
|
10
|
8
|
22
|
38
|
90
|
180
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
885
|
550
|
|
| Total Receivables |
180
|
324
|
302
|
254
|
312
|
369
|
408
|
|
| Accounts Receivables |
179
|
294
|
288
|
245
|
302
|
347
|
380
|
|
| Other Receivables |
1
|
30
|
15
|
9
|
10
|
22
|
28
|
|
| Inventory |
137
|
257
|
340
|
344
|
401
|
393
|
373
|
|
| Other Current Assets |
0
|
3
|
4
|
5
|
7
|
7
|
6
|
|
| Total Current Assets |
319
|
594
|
655
|
624
|
757
|
1 744
|
1 517
|
|
| PP&E Net |
243
|
317
|
332
|
385
|
384
|
415
|
540
|
|
| Intangible Assets |
4
|
5
|
5
|
5
|
4
|
7
|
16
|
|
| Other Long-Term Assets |
31
|
75
|
68
|
65
|
68
|
74
|
165
|
|
| Total Assets |
596
N/A
|
991
+66%
|
1 059
+7%
|
1 079
+2%
|
1 213
+12%
|
2 240
+85%
|
2 238
0%
|
|
| Liabilities | ||||||||
| Accounts Payable |
89
|
128
|
124
|
106
|
153
|
193
|
137
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
9
|
|
| Short-Term Debt |
227
|
397
|
402
|
388
|
379
|
200
|
84
|
|
| Current Portion of Long-Term Debt |
32
|
40
|
43
|
76
|
62
|
58
|
35
|
|
| Other Current Liabilities |
28
|
93
|
99
|
80
|
122
|
87
|
102
|
|
| Total Current Liabilities |
376
|
659
|
669
|
650
|
715
|
443
|
367
|
|
| Long-Term Debt |
38
|
64
|
146
|
107
|
104
|
76
|
43
|
|
| Deferred Income Tax |
0
|
0
|
0
|
8
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
11
|
9
|
9
|
13
|
20
|
19
|
|
| Other Liabilities |
32
|
104
|
110
|
108
|
113
|
126
|
143
|
|
| Total Liabilities |
445
N/A
|
839
+88%
|
934
+11%
|
881
-6%
|
944
+7%
|
665
-30%
|
571
-14%
|
|
| Equity | ||||||||
| Common Stock |
130
|
130
|
180
|
200
|
240
|
300
|
300
|
|
| Retained Earnings |
21
|
29
|
55
|
32
|
2
|
97
|
182
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
1 148
|
1 148
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
31
|
37
|
|
| Other Equity |
0
|
51
|
0
|
31
|
31
|
31
|
37
|
|
| Total Equity |
151
N/A
|
153
+1%
|
125
-18%
|
198
+58%
|
268
+35%
|
1 576
+487%
|
1 666
+6%
|
|
| Total Liabilities & Equity |
596
N/A
|
991
+66%
|
1 059
+7%
|
1 079
+2%
|
1 213
+12%
|
2 240
+85%
|
2 238
0%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
150
|
150
|
150
|
150
|
150
|
600
|
600
|
|
Switch to:
Switch to:
See Also
Discover More
